ALXO: מזומנים בחישוב למניה אחת alxoncology.com

Geopolitical risks and challenges with overseas trials are weighing on the development of ALX Oncology Holdings (ALXO). Cash per share reflects current liquidity, with 1.15 serving as the current value of this metric. ALX Oncology Holdings (ALXO) is scaling its Phase II/III trials by combining drugs with chemotherapy. The creation of an ecosystem based on CD47 blockers with evopacercept is designed to establish a new standard in cancer treatment.
פילוחי מדדים מקיפים ואנליטיקה עבור alxoncology.com (ALXO)

This indicator reflects the issuer's net liquidity, representing the difference between cash and short-term debt on a per-share basis. The metric allows investors to filter out speculative noise by assessing the actual financial safety cushion. By analyzing the amount of cash per share, an investor determines the company's ability to sustain its operating activities. For ALX Oncology Holdings (ALXO), this is critical due to the lack of revenue and dependence on the R&D pipeline. Controlling the cash burn rate here becomes the primary guarantee of business survival.